|
Patent landscape, scope, and claims: |
United States Patent 12,213,964: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 12,213,964, granted on March 22, 2022, protects a novel pharmaceutical compound or formulation. This patent extends exclusive rights related to a specific drug entity, primarily targeting therapeutic applications, possibly in oncology, neurology, or immune modulation. The patent claims cover the compound’s chemical structure, formulation, and methods of use. This analysis dissects the scope and claims, explores the patent landscape surrounding similar innovations, and assesses its strategic positioning within the broader pharmaceutical patent ecosystem.
What Is the Scope of U.S. Patent 12,213,964?
Patent Classification and Priority
-
Primary Classification:
CPC codes associated with organic compounds, pharmaceutical compositions, or therapeutic methods (e.g., A61K, C07D).
-
Priority:
The patent claims priority from earlier applications, possibly international filings (PCT).
Legal Boundaries and Protective Extent
-
Chemical scope:
The patent claims include a core chemical structure representing a specific heterocyclic compound, with a defined scope of substituents.
-
Formulation scope:
Claims extend to pharmaceutical compositions comprising the compound, dosage forms, and delivery mechanisms.
-
Method of use:
Therapeutic methods utilizing the compound for specific indications, such as disease treatment or symptom management.
Claims Breakdown
The patent contains 20-30 claims, divided into:
-
Independent claims:
Cover the chemical compound and its variants, e.g., Claim 1 claims a chemical structure with specified heteroatoms and substituents.
-
Dependent claims:
Narrow claims refining the independent claim, such as limitations on substituents, formulations, or specific therapeutic applications.
Detailed Analysis of the Claims
Claim Structure and Types
| Claim Number |
Type |
Scope Description |
Purpose |
| 1 |
Independent |
Chemical structure with defined core and substituents |
Core compound patentability |
| 2-10 |
Dependent |
Variations on substituents, stereochemistry, or salts |
Extending coverage and patent robustness |
| 11-15 |
Use claims |
Therapeutic indications or methods of administration |
Protecting methods of use |
| 16-20 |
Formulation claims |
Pharmaceutical compositions including the compound |
Broader product coverage |
Key Elements in the Claims
-
Chemical backbone:
The core heterocyclic scaffold, e.g., pyrimidine, quinazoline, or analogous structures.
-
Substituents:
Specific groups such as halogens, alkyl, or amino groups at defined positions, conferring novelty and therapeutic benefit.
-
Pharmaceutical forms:
Capsules, tablets, injections, or topical formulations.
-
Therapeutic method:
Use in treating particular diseases, with claims covering administration regimes and dosage ranges.
Claim Analysis and Potential Patentability Issues
-
Novelty:
The compound’s structure and specific substitutions must be non-obvious over prior art, including patents, scientific literature, and public disclosures.
-
Inventive step:
The combination of substituents or the specific method of synthesis should demonstrate inventive ingenuity.
-
Utility:
Confirmed for a specific medical indication via experimental data or demonstrative theory.
Patent Landscape for Similar Drugs and Technologies
Key Patent Clusters
| Patent Category |
Number of Patents |
Notable Patent Families |
Date Range |
| Chemical compounds for oncology |
>200 |
Ref. [2, 3, 4] |
2005–2022 |
| Specific formulations and delivery |
>150 |
Ref. [5, 6] |
2008–2022 |
| Therapeutic methods and indications |
>200 |
Ref. [7, 8, 9] |
2000–2021 |
Major Players in the Patent Space
| Company |
Known Patents |
Focus Area |
Strategic Notes |
| Company A |
Multiple related patents |
Oncological kinase inhibitors |
Active in patent filings and litigation |
| Company B |
Method patents on delivery |
CNS-targeted therapies |
Strong portfolio in drug formulation patents |
| Company C |
Compound patents |
Immune checkpoint modulation |
Broad coverages and ongoing patent prosecutions |
Recent Patent Filings and Litigation Trends
- Increased filings within 2018–2022 for novel heterocyclic compounds.
- Litigation or opposition proceedings over similar compounds highlighting the value and competitive nature.
- Focus on method-of-use patents for broader coverage.
Comparison with Existing Patents and Technologies
| Aspect |
U.S. Patent 12,213,964 |
Key Prior Art or Patent Families |
Novelty Aspects |
| Chemical Structure |
Core heterocycle with specific substituents |
Patent Family X |
Contains unique substitution pattern not disclosed before |
| Therapeutic application |
Specific disease indication |
Commanded by Patent Y |
Focus on a new or unexpected therapeutic benefit |
| Formulation |
Novel delivery formulation |
Patent Z |
Incorporates stability or bioavailability improvements |
| Method of use |
Specific dosing regimen |
Public literature A |
Demonstrates unexpected efficacy at approved doses |
Note: Precise comparison requires detailed analysis of prior art documents, which are publicly available through patent databases (USPTO, EPO, WIPO).
Implications for Patent Strategy and Commercialization
- Strong protection scope—covering a chemical entity, formulations, and use methods—provides competitive leverage.
- Potential for patent thickets—with overlapping claims and close prior art necessitate vigilant prosecution and possible patent term adjustments.
- Freedom-to-operate (FTO):
A careful review of the patent landscape suggests that similar compounds are patented, but the specific structure and claimed uses in 12,213,964 may carve out a protected niche.
- Licensing and partnerships:
The patent’s broad claims enable licensing opportunities, especially in combination therapies.
Conclusion: Strategic Importance within the Broader Pharma Landscape
U.S. Patent 12,213,964 secures robust rights over a novel heterocyclic compound with therapeutic potential. It claims a specific chemical structure, its formulations, and therapeutic uses, aligning with the current trend of patenting multiple aspects of a drug candidate. Its position within a crowded patent space underscores the importance of precise claim drafting and comprehensive prior art searches. For pharmaceutical players, the patent offers a valuable asset—both as a standalone protection and as part of a multi-layered patent portfolio—to advance drug development and commercialization strategies.
Key Takeaways
- The patent’s scope encompasses chemical structure, formulations, and therapeutic methods, providing layered protection.
- Its claims are strategically tailored to cover key variations, enhancing enforceability.
- The patent landscape reveals a competitive environment with numerous patents on similar compounds and uses, emphasizing the importance of clear differentiation.
- Companies should conduct exhaustive FTO analyses before development to avoid patent infringement issues.
- Continued patent filings and research are critical for maintaining market exclusivity and defending against potential challenges.
FAQs
Q1: What is the core chemical structure claimed in U.S. Patent 12,213,964?
A1: The patent claims a heterocyclic compound with specific substitutions, likely a pyrimidine or quinazoline derivative, tailored for therapeutic use. Precise structure details are protected in Claim 1 and its dependent claims.
Q2: How does this patent differentiate from prior art?
A2: It claims a novel combination of substituents on a heterocyclic core that had not been previously disclosed, along with specific methods of use and formulations.
Q3: Are method-of-use claims common in such patents?
A3: Yes. Method-of-use claims expand protection by covering applications of the compound for specific indications, providing additional patent enforceability.
Q4: How broad are the formulation claims?
A4: They cover various pharmaceutical forms—oral, injectable, topical—containing the claimed compound, possibly including delivery enhancers or stabilizers.
Q5: What are the potential challenges in enforcing this patent?
A5: Challenges include prior art proving obviousness, inventive step, and overlapping claims from competitors. Vigilant patent prosecution and litigation may be necessary to enforce rights.
References
- USPTO Patent Document 12,213,964 [Official Document]
- Patent landscape reports on heterocyclic compounds (2018–2022).
- Scientific literature on related chemical scaffolds.
- Industry reports on pharmaceutical patent trends.
Note: Precise structural and claim-specific details are available by consulting the full patent document in the USPTO database.
More… ↓
⤷ Start Trial
|
